Breast Cancer

The combination of ribociclib and letrozole resulted in a statistically significant improvement in overall survival vs letrozole alone in patients with postmenopausal, hormone receptor–positive, HER2-negative advanced breast cancer, with this benefit continuing to increase over time, supporting the use of this combination as a frontline treatment in this population.

Sara A. Hurvitz, MD, discusses the benefit of trastuzumab deruxtecan in a subset of patients with HER2-positive breast cancer and active brain metastases in the phase 3 DESTINY-Breast03 trial.

Sara M. Tolaney, MD, MPH, discusses pivotal trials in HER2-positive breast cancer.

The United Kingdom’s National Institute for Health and Clinical Excellence has issued draft guidance recommending against pembrolizumab plus chemotherapy as a treatment for patients with metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score of 10 or more and who have not received chemotherapy for metastatic disease.

Clinical outcomes achieved with talazoparib in a real-world population of patients with HER2-negative, locally advanced or metastatic breast cancer harboring germline BRCA mutations proved to be consistent with those observed in the phase 3 EMBRACA trial.

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Antibody-drug conjugates are innovative and effective therapeutic agents that have transformed the treatment landscape for patients with HER2-positive breast cancer and triple-negative breast cancer.

Sacituzumab govitecan resulted in a statistically significant improvement in progression-free survival vs physician’s choice of chemotherapy in patients with hormone receptor–positive, HER2-negative metastatic breast cancer who previously received endocrine therapy, CDK4/6 inhibitors, and 2 to 4 lines of chemotherapy, meeting the primary end point of the phase 3 TROPiCS-02 trial.

Several factors aid treatment selection for patients with newly diagnosed metastatic triple-negative breast cancer, with upfront PD-L1 and BRCA testing being the most critical biomarkers to examine.

The combination of adjuvant abemaciclib and endocrine therapy led to a clinically meaningful benefit at 3 years in patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer.

Clinicians with patients who are experiencing cardiotoxicity as a result of their breast cancer treatment should address the cardiotoxicity using a team-oriented approach based on guideline-directed therapies.

Elacestrant was found to result in a statistically significant and clinically meaningful improvement in progression-free survival over standard-of-care treatment in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who previously received CDK4/6 inhibitors.

Patrick Borgen, MD, discusses the evolution of immuno-oncology clinical trials in breast cancer.

Debu Tripathy, MD, discusses the emergence of genomics research in breast cancer.

CDK4/6 inhibitors in the metastatic setting have demonstrated clinical benefit in the hormone receptor–positive breast cancer population, leading to curiosity of its activity in early-stage patients and setting the stage for a handful of informative clinical trials.

Immunotherapy treatment for early-stage triple-negative breast cancer is enjoying a boom period, though there are still unanswered questions, particularly around the optimal chemotherapy backbone and patient selection.

Getting a start in clinical research can appear daunting, said Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C). Fortunately, all it really takes is a question and a bit of drive.

Pat W. Whitworth, MD, explains how data from past studies are informing the use of circulating tumor DNA and talks about the potential of these assays to guide treatment decisions in patients with breast cancer.

Charles L. Loprinzi, MD, discusses some of the most common treatment-related toxicities in breast cancer and provided insight into various current and investigational approaches available to patients.

Patients with newly diagnosed metastatic triple-negative breast cancer should undergo PD-L1 expression testing on tumors to determine whether they are candidates for frontline chemoimmunotherapy.

Treatment with eribulin elicited an estimated 2-year overall survival rate of 53.6% for patients with metastatic breast cancer previously treated with atezolizumab or sacituzumab govitecan, according to real-world findings.

Sara A. Hurvitz, MD, discusses utilizing CDK4/6 inhibitors in hormone receptor-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the efficacy of trastuzumab deruxtecan in the second-line setting and its potential to move into the first-line treatment of HER2-positive breast cancer.

The 39th Annual Miami Breast Cancer Conference® makes its return to the Fontainebleau Miami Beach in Florida with a twist on both the agenda and the setting.

A panel of experts briefly reviews the treatment options available for patients with ER+, HER2+ metastatic breast cancer.

Expert panelists discuss the optimal management patients with special subsets of HER2+ metastatic breast cancer, such as HR+ or HER2-low disease.

Tiffany A. Traina, MD, discusses the implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase Cancer Center, was recently awarded a $50,000 grant from the Pennsylvania Breast Cancer Coalition.

From early phase 1/2 to pivotal phase 3 data, the 2021 San Antonio Breast Cancer Symposium was full of exciting research with selective estrogen receptor degraders, CDK4/6 inhibitors, and antibody-drug conjugates.